About Grail Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://grail.com/
Frequently Asked Questions
What is the 52-week range for GRAL?
The 52-week high is $151.4574 and the 52-week low is $41.5.
What is the P/E ratio for GRAL?
The P/E ratio data is currently unavailable.
What is the dividend yield for GRAL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -15.88%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -236.95%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.29.
Analyst Recommendation Trends
Wall Street analyst consensus for GRAL over the last few months:
Latest GRAL News
Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results
In September 2026, GRAIL announced that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the...
UBS Maintains Buy on GRAIL, Raises Price Target to $175
UBS analyst Doug Schenkel maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $105 to $175.
Guggenheim Maintains Buy on GRAIL, Raises Price Target to $155
Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $75 to $155.
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
The cancer blood test maker could have a bright future.
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
A positive FDA vote is driving the recent surge in the multi-cancer early detection (MCED) test company.
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
Grail stock has catapulted, reaching a record high, as the FDA mulls its contender in the multibillion-dollar cancer detection market.
GRAIL: AdCom's Vote Of Confidence Is Significant
The company gained the FDA advisory committee's positive recommendation, making GRAL more likely to gain FDA approval for Galleri. Click to read.
Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $150
Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $80 to $150.
Micron, Nike To Headline Earnings Next Week; GDP Numbers Awaited
Wall Street Week Ahead: key market events, earnings (MU, NKE), IPOs (OURA), and major economic data. See here for more details.
Here's Why Grail Stock Surged 55% This Week
The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $65 to $100.
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued?
GRAIL (GRAL) is back in focus after the FDA's Medical Devices Advisory Committee backed its Galleri multi cancer early detection test, shortly after strong PATHFINDER 2 data in Nature Medicine reinforced its real world performance. That regulatory drumbeat has shown up quickly in the chart. GRAIL’s share price has climbed sharply in recent weeks, with a 7 day share price return of 35.73% and a 90 day share price return of 64.62%. The 1 year total shareholder return of 124.87% points to strong...
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test
Grail stock surged Thursday after a panel of advisors to the FDA backed the company's cancer-detecting blood test.
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers.
Dow Jones futures fell early Thursday, along with S&P 500 futures and especially Nasdaq futures. The 30-year Treasury yield hit a fresh long-term high while oil prices rose again. The Trump-Xi summit is on tap.
The Holy Grail In Cancer? FDA Panel Backs Blood Tests
Grail stock was halted Wednesday after an Food and Drug Administration panel discussed the company's blood screening test for cancer.
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) application of the Galleri® multi-cancer early detection test (MCED).
U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use
https://www.fda.gov/media/194909/download
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade
Meta's agentic AI assistant Muse lit a fire under tech on Monday, pushing the Nasdaq to a record close and lifting chipmakers by double digits. Cheaper oil, a ten-year yield back below 5% and a friendlier tone between Washington and Beijing did the rest, while Paramount cleared the last big hurdle for its Warner Bros. Discovery takeover.
Baird Maintains Outperform on GRAIL, Raises Price Target to $118
Baird analyst Catherine Schulte maintains GRAIL (NASDAQ:GRAL) with a Outperform and raises the price target from $96 to $118.
GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why.
Key TakeawaysFDA Signal: GRAIL stock jumped 34% on Monday after FDA staff found no major safety or accuracy issues with the Galleri cancer test. Street Gap: TIKR tracks 11 analysts on GRAL stock, split 5 buys and 6 holds, and their $79 mean target now sits 27% below Monday’s $108 close, a gap the Street hasn’t caught up to yet.
GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on Sept. 23 to discuss Grail’s application seeking approval of its cancer detection test.
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday.
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge
Grail stock surges on favorable FDA briefing documents back its Galleri multi-cancer test ahead of the September 23 advisory committee vote.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47% to $106.19.
The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
Critical Metals, Priority Technology, Meta Platforms And Other Big Stocks Moving Higher On Monday
U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tech and other shares broadly gained.
Grail Analyst Sees Massive Market Potential with Valuation Headwinds
Grail "is a pure play," according to RBC Capital Markets. The company offers a tool for screening malignancies that lack standard protocols.
GRAIL Q2 2026 Earnings Call: Complete Transcript
On Wednesday, GRAIL (NASDAQ:GRAL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
RBC Capital Initiates Coverage On GRAIL with Sector Perform Rating, Announces Price Target of $84
RBC Capital analyst Dan Leonard initiates coverage on GRAIL (NASDAQ:GRAL) with a Sector Perform rating and announces Price Target of $84.
GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GRAIL, Inc. (GRAL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 11:30 AM EDTCompany ParticipantsEric Fung - Senior Vice...
UBS Initiates Coverage On GRAIL with Buy Rating, Announces Price Target of $105
UBS analyst Doug Schenkel initiates coverage on GRAIL (NASDAQ:GRAL) with a Buy rating and announces Price Target of $105.
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000
An insider sells 7,900 shares as the stock price has surged over the past year.
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Freidin Aaron | -521 | $95 | $49,495 |
| 2026-09-21 | Freidin Aaron | -1,800 | $93.9156 | $169,048 |
| 2026-09-21 | Freidin Aaron | -1,779 | $92.2631 | $164,136 |
| 2026-09-21 | Ofman Joshua J. | -26,452 | - | - |
| 2026-09-21 | Ofman Joshua J. | -10,000 | $110 | $1,100,000 |
| 2026-09-21 | Ofman Joshua J. | -2,100 | $100.6805 | $211,429 |
| 2026-09-21 | Ofman Joshua J. | -421 | $99.8499 | $42,037 |
| 2026-09-21 | Ofman Joshua J. | -1,400 | $97.8414 | $136,978 |
| 2026-09-21 | Ofman Joshua J. | -6,200 | $96.4308 | $597,871 |
| 2026-09-21 | Ofman Joshua J. | -37,752 | $94.9828 | $3,585,791 |
| 2026-09-21 | Ofman Joshua J. | -1,454 | $93.606 | $136,103 |
| 2026-09-21 | Ofman Joshua J. | -2,125 | $92.3152 | $196,170 |
| 2026-09-21 | Ofman Joshua J. | +26,452 | $14 | $370,328 |
| 2026-08-27 | Ofman Joshua J. | -5,000 | $85.0196 | $425,098 |
| 2026-08-27 | Freidin Aaron | -7,900 | $85.01 | $671,579 |
| 2026-07-15 | CHASE WILLIAM J | +276 | $74.36 | $20,523 |
| 2026-07-15 | MIZELL STEVEN | +268 | $74.36 | $19,928 |
| 2026-07-15 | SUMME GREGORY L | +427 | $74.36 | $31,752 |
| 2026-06-18 | Krevans Sarah | +5,491 | $63.74 | $349,996 |
| 2026-06-18 | CHASE WILLIAM J | +5,491 | $63.74 | $349,996 |
| 2026-06-18 | MIZELL STEVEN | +5,491 | $63.74 | $349,996 |
| 2026-06-18 | SUMME GREGORY L | +5,491 | $63.74 | $349,996 |
| 2026-06-04 | Partridge Andrew John | -1,491 | $61.08 | $91,070 |
| 2026-06-03 | Ofman Joshua J. | +3,154 | $61.13 | $192,804 |
| 2026-06-01 | Ofman Joshua J. | +27,901 | $64.4 | $1,796,824 |
| 2026-04-15 | CHASE WILLIAM J | +408 | $49.79 | $20,314 |
| 2026-04-15 | MIZELL STEVEN | +396 | $49.79 | $19,717 |
| 2026-04-15 | SUMME GREGORY L | +631 | $49.79 | $31,417 |
| 2026-04-08 | Freidin Aaron | -45,806 | $49.9176 | $2,286,526 |
| 2026-04-08 | Ofman Joshua J. | -61,665 | $49.9176 | $3,078,169 |
| 2026-04-08 | RAGUSA ROBERT P | -123,502 | $49.9176 | $6,164,923 |
| 2026-03-09 | Freidin Aaron | -85 | $46.74 | $3,973 |
| 2026-03-09 | Freidin Aaron | -2,407 | $47.93 | $115,368 |
| 2026-03-09 | Ofman Joshua J. | -101 | $46.74 | $4,721 |
| 2026-03-09 | Ofman Joshua J. | -2,836 | $47.93 | $135,929 |
| 2026-03-09 | RAGUSA ROBERT P | -258 | $46.73 | $12,056 |
| 2026-03-09 | RAGUSA ROBERT P | -7,203 | $47.93 | $345,240 |
| 2026-03-05 | Freidin Aaron | -655 | $53.01 | $34,722 |
| 2026-03-05 | Ofman Joshua J. | -690 | $53.01 | $36,577 |
| 2026-03-05 | RAGUSA ROBERT P | -980 | $53.01 | $51,950 |
| 2026-03-02 | Ofman Joshua J. | -16,223 | $50.0853 | $812,534 |
| 2026-03-02 | Ofman Joshua J. | -779 | $51.7509 | $40,314 |
| 2026-03-02 | Freidin Aaron | -438 | $51.8611 | $22,715 |
| 2026-03-02 | Freidin Aaron | -9,135 | $50.0853 | $457,529 |
| 2026-03-02 | RAGUSA ROBERT P | -1,717 | $51.843 | $89,014 |
| 2026-03-02 | RAGUSA ROBERT P | -35,787 | $50.0853 | $1,792,403 |
| 2026-02-27 | Ofman Joshua J. | +84,540 | $53.23 | $4,500,064 |
| 2026-02-27 | Freidin Aaron | +60,118 | $53.23 | $3,200,081 |
| 2026-01-15 | CHASE WILLIAM J | +213 | $97.44 | $20,755 |
| 2026-01-15 | MIZELL STEVEN | +206 | $97.44 | $20,073 |
| 2026-01-15 | SUMME GREGORY L | +329 | $97.44 | $32,058 |
| 2025-12-03 | Ofman Joshua J. | -13,000 | $100 | $1,300,000 |
| 2025-12-03 | Freidin Aaron | -25,000 | $99.1527 | $2,478,818 |
| 2025-12-03 | RAGUSA ROBERT P | -1,604 | $97.2831 | $156,042 |
| 2025-12-03 | RAGUSA ROBERT P | -8,233 | $96.2167 | $792,152 |
| 2025-12-03 | RAGUSA ROBERT P | -15,356 | $95.2782 | $1,463,092 |
| 2025-12-03 | RAGUSA ROBERT P | -14,807 | $94.4316 | $1,398,249 |
| 2025-11-17 | Freidin Aaron | -1,697 | $79.2 | $134,402 |
| 2025-11-17 | ILLUMINA, INC. | -1,000,000 | $79.85 | $79,850,000 |
| 2025-10-16 | Ofman Joshua J. | -6,114 | $82.01 | $501,409 |
| 2025-10-15 | Ofman Joshua J. | -8,865 | $76.0276 | $673,985 |
| 2025-10-15 | CHASE WILLIAM J | +275 | $75.52 | $20,768 |
| 2025-10-15 | RAGUSA ROBERT P | -7,239 | $68.88 | $498,622 |
| 2025-10-15 | MIZELL STEVEN | +267 | $75.52 | $20,164 |
| 2025-10-15 | SUMME GREGORY L | +425 | $75.52 | $32,096 |
| 2025-10-06 | Ofman Joshua J. | -81,385 | $62.5 | $5,086,563 |